Denosumab for osteoporosis reduced fracture risk by 45% but raised the risk of major adverse cardiovascular events by 36% in dialysis-dependent patients, prompting calls for further research.
Read More
The acquisition will expand Boston Scientific’s cardiovascular portfolio with a complementary and differentiated calcium modification platform, furthering the company’s strategy to address coronary and peripheral disease.
Read More
Researchers find that when you drink coffee matters, with timing influencing reductions in heart disease and death risk.
Read More
A phase 2 trial will evaluate the drug’s potential to reduce upper airway obstruction and nocturnal hypertension in patients with moderate-to-severe OSA.
Read More
Surgeon-scientists analyze the case of Lawrence Faucette, the second recipient of a genetically modified pig heart, to identify challenges to avoid rejection in future xenotransplants.
Read More